Now showing items 1-2 of 2

    • Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. 

      Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; Driscoll, CB; Schuelke, M; Shim, KG; Wongthida, P; Ilett, EJ; Smith, KK; Harris, RS; Coffey, M; Pulido, JS; Pandha, H; Selby, PJ; Harrington, KJ; Melcher, A; Vile, RG (2019-05)
      Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ...
    • Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. 

      Kottke, T; Evgin, L; Shim, KG; Rommelfanger, D; Boisgerault, N; Zaidi, S; Diaz, RM; Thompson, J; Ilett, E; Coffey, M; Selby, P; Pandha, H; Harrington, K; Melcher, A; Vile, R (2017-11)
      Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition ...